|Bid||215.00 x 800|
|Ask||275.00 x 900|
|Day's range||218.00 - 227.95|
|52-week range||181.00 - 324.81|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||356.38|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||273.62|
While Insulet Corporation ( NASDAQ:PODD ) shareholders are probably generally happy, the stock hasn't had particularly...
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
ACTON, Mass., June 03, 2022--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) study results for very young children with type 1 diabetes. Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 yea